Trial reportBlood2012
Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.
Trial report in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 131 citations in OpenAlex.
- Chemokines as novel and versatile reagents for flow cytometry and cell sorting.Journal of immunology (Baltimore, Md. : 1950) · 2014Trial
- NK cell immunotherapy after analytic treatment interruption is associated with HIV viral control.Molecular therapy. Advances · 2026Article
- Multiplex engineering of rhesus macaque NK cells enhances homing to sites of HIV replication in B cell follicles.bioRxiv : the preprint server for biology · 2026Article
- Programmable macromolecule delivery via engineered trogocytosis.Nature cell biology · 2026Article
- Redirecting engineered immune cells using G protein-coupled receptors in cancer therapy.Immuno-oncology technology · 2026Review
- CAR-NK Engineering to Overcome TME Barriers.Cells · 2025Review
- NK cell immunotherapy administered at the time of HIV recrudescence is associated with viral control.bioRxiv : the preprint server for biology · 2025Article
- CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization.Cell communication and signaling : CCS · 2025Review
- Engineered natural killer cells for cancer therapy.Cancer cell · 2025Review
- The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies.Cancer cell international · 2025Review
- CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors.Vaccines · 2025Review
- Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non-Viral CAR-NK Cell Engineering.Cell proliferation · 2025Review
- Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1-infected CD4+ T cells by ADCC.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy.Frontiers in pharmacology · 2025Review
- Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy.Pharmaceutics · 2024Review
- NK Cells in the Lymph Nodes and Their Role in Anti-Tumour Immunity.Biomedicines · 2024Review
- Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity.NPJ precision oncology · 2024Article
- Development of NK cell-based cancer immunotherapies through receptor engineering.Cellular & molecular immunology · 2024Review
- Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells.Molecular therapy. Oncology · 2024Article
- Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside.Cell death & disease · 2024Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Natural killer (NK) cells have gained significant attention in adoptive immunotherapy for cancer. Consequently, novel methods of clinical-grade expansion of NK cells have emerged. Subsets of NK cells express a variety of chemokine receptors. However, to expand the scope of adoptively transferred NK cell homing to various malignancies, expression of corresponding chemokine receptors on NK cells is essential. Here, we have explored the use of trogocytosis as a tool to transiently express the chemokine receptor CCR7 on expanded human NK cells with the aim to enhance their homing to lymph nodes. We generated a K562-based "donor" cell line expressing CCR7, Clone9.CCR7, to transfer CCR7 onto NK cells via trogocytosis. CCR7 expression occurred in 80% of expanded NK cells within 1 hour after coculture with Clone9.CCR7. After removal of the donor cells from the coculture, the CCR7 expression on NK cells steadily declined to baseline levels by 72 hours. The acquired CCR7 receptors mediated in vitro migration of NK cells toward CCL19 and CCL21 and increased the lymph node homing by 144% in athymic nude mice. This is the first report on exploiting trogocytosis to rapidly and transiently modify lymphocytes, without direct genetic intervention, for adoptive transfer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.